311 related articles for article (PubMed ID: 27287851)
1. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
[TBL] [Abstract][Full Text] [Related]
2. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
McPhee F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Yu ML; Ahn SH; Ishikawa H; Bhore R; Zhou N; Hernandez D; Mendez P; Kumada H
Adv Ther; 2015 Jul; 32(7):637-49. PubMed ID: 26155891
[TBL] [Abstract][Full Text] [Related]
3. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.
Kosaka K; Imamura M; Hayes CN; Abe H; Hiraga N; Yoshimi S; Murakami E; Kawaoka T; Tsuge M; Aikata H; Miki D; Ochi H; Matsui H; Kanai A; Inaba T; Chayama K
J Viral Hepat; 2015 Feb; 22(2):158-65. PubMed ID: 24943406
[TBL] [Abstract][Full Text] [Related]
4. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
Yu JH; Lee JI; Lee KS; Kim JK
Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
[TBL] [Abstract][Full Text] [Related]
5. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
Teraoka Y; Uchida T; Imamura M; Hiraga N; Osawa M; Kan H; Saito Y; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
J Gen Virol; 2018 Aug; 99(8):1058-1065. PubMed ID: 29916799
[TBL] [Abstract][Full Text] [Related]
6. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
Kao JH; Lee YJ; Heo J; Ahn SH; Lim YS; Peng CY; Chang TT; Torbeyns A; Hughes E; Bhore R; Noviello S
Liver Int; 2016 Oct; 36(10):1433-41. PubMed ID: 27009831
[TBL] [Abstract][Full Text] [Related]
7. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
Yoshimi S; Imamura M; Murakami E; Hiraga N; Tsuge M; Kawakami Y; Aikata H; Abe H; Hayes CN; Sasaki T; Ochi H; Chayama K
J Med Virol; 2015 Nov; 87(11):1913-20. PubMed ID: 25954851
[TBL] [Abstract][Full Text] [Related]
8. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
[TBL] [Abstract][Full Text] [Related]
9. Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
Ikeda H; Watanabe T; Okuse C; Matsumoto N; Ishii T; Yamada N; Shigefuku R; Hattori N; Matsunaga K; Nakano H; Hiraishi T; Kobayashi M; Yasuda K; Yamamoto H; Yasuda H; Kurosaki M; Izumi N; Yotsuyanagi H; Suzuki M; Itoh F
J Med Virol; 2017 Jan; 89(1):99-105. PubMed ID: 27329864
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
Iio E; Shimada N; Abe H; Atsukawa M; Yoshizawa K; Takaguchi K; Eguchi Y; Nomura H; Kuramitsu T; Kang JH; Matsui T; Hirashima N; Tsubota A; Kusakabe A; Hasegawa I; Miyaki T; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
J Gastroenterol; 2017 Jan; 52(1):94-103. PubMed ID: 27236547
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
Yu ML; Hung CH; Huang YH; Peng CY; Lin CY; Cheng PN; Chien RN; Hsu SJ; Liu CH; Huang CF; Su CW; Huang JF; Liu CJ; Kao JH; Chuang WL; Chen PJ; Chen DS
J Formos Med Assoc; 2019 Feb; 118(2):556-564. PubMed ID: 30527566
[TBL] [Abstract][Full Text] [Related]
12. New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
Mawatari S; Oda K; Tabu K; Ijuin S; Kumagai K; Inada Y; Uto H; Hiramine Y; Kure T; Fujisaki K; Hashiguchi M; Hori T; Oshige A; Imanaka D; Saishoji A; Taniyama O; Sakae H; Tamai T; Moriuchi A; Ido A
J Gastroenterol; 2017 Jul; 52(7):855-867. PubMed ID: 28078469
[TBL] [Abstract][Full Text] [Related]
13. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.
Kanda T; Yasui S; Nakamura M; Suzuki E; Arai M; Haga Y; Sasaki R; Wu S; Nakamoto S; Imazeki F; Yokosuka O
Int J Med Sci; 2016; 13(6):418-23. PubMed ID: 27279790
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.
Wang HL; Lu X; Yang X; Xu N
J Gastroenterol Hepatol; 2017 Jan; 32(1):45-52. PubMed ID: 27597318
[TBL] [Abstract][Full Text] [Related]
15. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Hong CM; Liu CJ; Yeh SH; Chen PJ
J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
[TBL] [Abstract][Full Text] [Related]
16. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
[TBL] [Abstract][Full Text] [Related]
17. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Hirooka Y; Goto H
J Med Virol; 2018 Apr; 90(4):736-744. PubMed ID: 29111616
[TBL] [Abstract][Full Text] [Related]
18. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Toyota J; Karino Y; Suzuki F; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; Hu W; McPhee F; Linaberry M; Yin PD; Swenson ES; Kumada H
J Gastroenterol; 2017 Mar; 52(3):385-395. PubMed ID: 27502287
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
Morio R; Imamura M; Kawakami Y; Morio K; Kobayashi T; Yokoyama S; Kimura Y; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Nelson Hayes C; Aikata H; Takahashi S; Miki D; Ochi H; Mori N; Takaki S; Tsuji K; Chayama K
J Gastroenterol; 2017 Apr; 52(4):504-511. PubMed ID: 27631593
[TBL] [Abstract][Full Text] [Related]
20. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
